Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Novo Nordisk (NVO) closed the most recent trading ... Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand ...

The future of GLP-1 drugs is looking bigger than anyone predicted. As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this ...

I see that Novo Nordisk is cheaper than its main competitor ... clear signs of a turnaround in investor sentiment. Don't get me wrong. In the long term, I believe the company is a solid buy.

Novo Nordisk A/S’s blockbuster drug Wegovy was ... 17.5% reduction among people who got a standard dose — but was less than either the highest dose of Eli Lilly & Co.’s Zepbound or the ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...